TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A federal settlement announced October 13 requires CVS to block controlled-substance prescriptions from certain prescribers, including those whose credentials are suspended or revoked and those with unresolved prescribing concerns after review. The agreement does not expressly require CVS to assess what happens to patients after a block. Researchers say outcome tracking could help determine whether the restrictions reduce harm while connecting patients to appropriate care.
A $315 million settlement announced October 13 requires CVS to block controlled-substance prescriptions from certain prescribers, including some with suspended or revoked credentials and those whose prescribing concerns remain unresolved after review. The agreement resolves federal allegations without an admission of liability, and its memorandum does not expressly require assessment of patients’ health after a block, according to a MedPage Today report published October 21.
The accompanying Drug Enforcement Administration memorandum requires CVS to block prescriptions from prescribers whose DEA registration or state license has been suspended or revoked. It also requires CVS to block a prescriber across its retail pharmacies when prescribing concerns remain unresolved after review, unless prohibited by law. CVS must report blocked prescribers, but the memorandum does not expressly require tracking their patients’ subsequent outcomes.
The settlement resolves federal allegations of unlawful dispensing and false claims; CVS did not admit liability, according to the report. The source material does not detail the allegations, CVS’s response, or the settlement’s payment schedule. The report also notes that comparable provisions appeared in a 2022 multistate settlement involving CVS.
Alex Smolak, PhD, writing in MedPage Today, argues that restricting dispensing and reducing patients’ overall health risks are related but distinct goals. Patients whose prescriptions come from a blocked prescriber may need reassessment, care for physical dependence, or treatment for opioid use disorder. A pharmacy restriction alone does not establish whether they reach safer care, lose access to needed treatment, or obtain prescriptions elsewhere.
Tracking Care After a Block
The policy is intended to stop dispensing linked to prescribing concerns, but a lower volume of CVS prescriptions is not enough to show a clinical benefit. Patients might move to another pharmacy, find an appropriate clinician, or face a gap in treatment. Those outcomes have different implications for safety, and the block itself does not distinguish among them.
Smolak proposes an independent evaluation that follows patients across care settings. One possible starting point would link CVS block dates to pharmacy and medical insurance claims, then compare patients’ later treatment and emergency visits with carefully selected comparison groups and prior trends. Such work could examine whether restrictions correspond with safer treatment and fewer adverse events, while also looking for interruptions in care.
That evidence would matter to patients, clinicians, regulators, and policymakers evaluating whether enforcement measures achieve their intended purpose without leaving patients’ health needs unaddressed. CVS dispensing records alone cannot show what happened at other pharmacies or in care outside the company’s records.
Popular right now
Vitamix 5200 Professional-Grade Blender, 64 oz. Container, Black
TCL QM64L 85-Inch QD-Mini LED 4K Smart Fire TV
Vitamix Propel Series 750 Professional-Grade Blender, 4 Programs, Black
As an affiliate, we earn on qualifying purchases.
The Settlement’s Patient-Care Gap
Federal allegations addressed by the agreement involved unlawful dispensing and false claims, as described in the report. Medically unnecessary opioids and dangerous combinations of controlled substances can expose patients to overdose and death. The settlement’s blocking provisions address dispensing by prescribers who meet specified credential or review criteria.
Smolak notes that similar provisions were included in CVS’s 2022 multistate settlement, making the latest requirements part of an established approach rather than an entirely new measure. His commentary focuses on what reporting should add: an assessment of patients’ care and health after their prescriber is blocked, not only a record of which prescribers were restricted.
The report cites FDA warnings about severe withdrawal, uncontrolled pain, and suicide after rapid opioid reduction or abrupt discontinuation in physically dependent patients. It also cites CDC guidance against rigid restrictions and patient abandonment, and a JAMA observational study that associated tapering among patients on stable, long-term, higher-dose opioids with higher rates of overdose and mental-health crises. These findings concern treatment disruption or tapering; they do not establish that CVS prescriber blocks cause the same outcomes.
“Stopping harmful prescribing and reducing the patient’s overall risk belong in the same intervention.”
— Alex Smolak, PhD, in MedPage Today
Patient Outcomes Remain Unmeasured
The settlement memorandum, as described in the report, requires reporting of blocked prescribers but does not expressly require assessment of their patients’ later health outcomes. The source material does not establish how many prescribers or patients will be affected, how quickly restrictions will occur, or whether CVS or another party will conduct follow-up research.
It is also unknown whether patients will obtain appropriate care elsewhere, continue a potentially dangerous regimen through another pharmacy, or experience a prolonged interruption. Insurance claims can miss pain, functioning, and care outside the coverage system. Any later study would also need to account for patients’ pre-existing risks and the reasons their prescribers were blocked. An adverse event occurring after a block would not, by itself, show that the restriction caused it.
Evaluating Care After Restrictions
The settlement’s immediate requirements include blocking qualifying prescriptions and reporting blocked prescribers. No patient-outcome evaluation or timeline for one is specified in the supplied report. Smolak recommends beginning with an independent study that links block dates to pharmacy and medical claims for patients who had filled opioid prescriptions from those prescribers.
Researchers could track treatment gaps, later dispensing, and emergency visits, comparing results with suitable patients and earlier trends. Medical records and patient accounts could help fill gaps in claims data. The next meaningful evidence would show whether patients moved to safer treatment and whether their health outcomes changed, while carefully separating effects of the block from risks that existed before it.
Key Questions
What does the CVS settlement require?
The DEA memorandum requires CVS to block controlled-substance prescriptions from prescribers whose DEA registration or state license is suspended or revoked. It also requires blocks across CVS retail pharmacies for prescribers whose concerns remain unresolved after review, unless prohibited by law.
Does the agreement require CVS to track patients after a block?
According to the report, the memorandum requires reporting of blocked prescribers but does not expressly require assessment of their patients’ subsequent health outcomes.
Does the settlement prove that CVS violated the law?
The agreement resolves federal allegations involving unlawful dispensing and false claims. The report says it does so without an admission of liability.
Could patients lose access to opioid treatment after a prescriber is blocked?
The report says several outcomes are possible: a patient may receive care from another clinician, obtain prescriptions elsewhere, or experience an interruption. The supplied material does not establish how often any of these outcomes will occur.
Would an adverse event after a block show that the block caused it?
No. The report says patients may already face elevated risks because of their health conditions or the prescribing that prompted intervention. A study would need to account for those factors; timing alone would not establish cause.
Source: rss
